Physiological melatonin inhibition of human breast cancer cell growth in vitro: Evidence for a glutathione-mediated pathway

Cancer Research

Volumn 57, Issue 10, 1997, Pages 1909-1914

  Blask, David E ^a   Wilson, Scan T ^a   Zalatan, Fred ^a  

^a BASSETT RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BUTHIONINE SULFOXIMINE; ENZYME INHIBITOR; ESTROGEN RECEPTOR; GLUTAMATE CYSTEINE LIGASE; GLUTATHIONE; MELATONIN;

ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER GROWTH; CANCER INHIBITION; CELL GROWTH; CONTROLLED STUDY; CYTOTOXICITY; ENZYME INHIBITION; FEMALE; HORMONAL REGULATION; HUMAN; HUMAN CELL; PRIORITY JOURNAL;

ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; BUTHIONINE SULFOXIMINE; CELL DIVISION; DIURETICS; ETHACRYNIC ACID; FEMALE; GLUTATHIONE; HUMANS; MELATONIN; RECEPTORS, ESTROGEN; TAMOXIFEN; TUMOR CELLS, CULTURED;

EID: 0030951234     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (67)

1. Blask, D. E. The pineal: an oncostatic gland? In: R. J. Reiter (ed.), The Pineal Gland, pp. 253-284. New York: Raven Press, 1984.
2. Blask, D. E., and Hill, S. M. Melatonin and cancer: basic and clinical perspectives. In: A. Miles, D. R. S. Philbrick, and C. Thompson (eds.), Melatonin: Clinical Perspectives, pp. 128-173. New York: Oxford University Press, 1988.
3. Blask, D. E. Melatonin in oncology. In: H. S. Yu and R. J. Reiter (eds.), Melatonin, Biosynthesis, Physiological Effects, and Clinical Applications, pp. 447-475. Boca Raton, FL: CRC press, Inc., 1993.
4. Wrba, H., Halberg, F., and Dutter, A. Melatonin circadian-stage-dependency delays breast tumor development in mice injected daily for several months. Chronobiologia, 13: 123-126, 1986.
5. Subramanian, A., and Kothari, L. Melatonin, a suppressor of spontaneous murine mammary tumors. J. Pineal Res., 10: 136-140, 1991.
6. Anisimov, V. N., Morozov, V. G., Kbvavinson, V. K., and Dilman, V. M. Correlations of antitumor activity of pineal and hypothalamic extract, melatonin and sygethin in mouse transplantable mammary tumors. Vopr. Onkol., 19: 99-101, 1973.
7. Karmali, R. A., Horrobin, D. F., and Ghayur, T. Role of the pineal gland in the aetiology and treatment of breast cancer. Lancet, 2: 1001-1002, 1978.
8. Aubert, C., Janiaud, P., and Lecalvez, J. Effect of pinealectomy and melatonin on mammary tumor growth in Sprague-Dawley rats under conditions of lighting. J. Neural Transm., 47: 121-130, 1980.
9. Tamarkin, L., Cohen, M., Roselle, D., Reichert, C., Lippman, M., and Chabner, B. Melatonin inhibition of pinealectomy enhancement of 7,12-dimethylbenzanthracene-induced mammary tumors in the rat. Cancer Res., 41: 4432-4436, 1981.
10. Shah, P. N., Mhatre, M. C., and Kothari, L. S. Effect of melatonin on mammary carcinogenesis in intact and pinealectomized rats in varying photoperiods. Cancer Res., 44: 3403-3407, 1984.
11. Blask, D. E., Hill, S. M., Orstead, K. M., and Massa, J. S. Inhibitory effects of the pineal hormone melatonin and underfeeding during promotional phase of 7,12-dimethylbenzanthracene (DMBA)-induced mammary tumorigenesis. J. Neural Transm., 67: 125-138, 1986.
12. Kothari, L. Influence of chronic melatonin on 9,10-dimethyl-1,2-benzanthracene (DMBA)-induced mammary tumorigenesis. Oncology (Basel), 44: 64-66, 1987.
13. Blask, D. E., Pelletier, D. B., Hill, S. M., Lemus-Wilson, A., Grosso, D. S., Wilson, S. T., and Wise, M. E. Pineal melatonin inhibition of tumor promotion in the N-nitroso-N-methylurea model of mammary carcinogenesis: potential involvement of antiestrogenic mechanisms in vivo. J. Cancer Res. Clin. Oncol., 117: 526-532, 1991.
14. Subramanian, A., and Kothari, L. Suppressive effect by melatonin on different phases of 9,10-dimethyl-1,2-benzanthracene (DMBA)-induced rat mammary gland carcinogenesis. Anticancer Drugs, 2: 297-303, 1991.
15. Kothari, L., Shah, P. N., and Mhatre, M. C. Pineal ablation in varying photoperiods and the incidence of 9,10-dimethylbenzanthracene-induced mammary cancer in rats. Cancer Lett., 22: 99-102, 1984.
16. Reiter, R. J. The pineal and its hormones in the control of reproduction in mammals. Endocr. Rev., 1: 109-131, 1980.
17. Bartsch, C., Bartsch, H., Fuchs, U., Lippert, T. H., Bellman, O., and Gupta, D. Stage-dependent depression of melatonin in patients with primary breast cancer: correlation with prolactin, TSH, and steroid receptors. Cancer (Phila.), 64: 426-433, 1989.
18. Tamarkin, L., Danforth, D., Lichter, A., De Moss, E., Cohen, M., Chabner, B., and Lippman, M. Decreased nocturnal plasma melatonin peak in patients with estrogen receptor-positive breast cancer. Science (Washington DC), 216: 1003-1005, 1982.
19. Hill, S. M., and Blask, D. E. Effects of the pineal hormone melatonin on the proliferation and morphological characteristics of human breast cancer cells (MCF-7) in culture. Cancer Res., 48: 6121-6126, 1988.
20. Hill, S. M., Spriggs, L. L., Simon, M. A., Muraoka, H., and Blask, D. E. The growth-inhibitory action of melatonin on human breast cancer cells is linked to the estrogen response system. Cancer Lett., 64: 249-256, 1992.
21. Cos, S., and Blask, D. E. Effects of melatonin on anchorage-independent growth of human breast cancer cells (MCF-7) in a clonogenic culture system. Cancer Lett., 50: 115-119, 1990.
22. Cos, S., Blask, D. E., Lemus-Wilson, A., and Hill, A. B. Effects of melatonin on the cell cycle kinetics and estrogen-rescue of MCF-7 human breast cancer cells in culture. J. Pineal Res., 10: 36-42, 1991.
23. de Launoit, Y., Pasteels, J. L., L'Hermite, M., and L'Hermite-Baleriaux, M. In vitro effect of melatonin on cell cycle kinetics of mammary cancer cell lines. Endocr. Soc., 72: 59, 1990.
24. L'Hermite-Baleriaux, M., L'Hermite, M., Pasteels, J. L., and de Launoit, Y. Effect of melatonin on the proliferation of human mammary cancer cells in culture. Eur. Pineal Study Grp., , 1990.
25. + breast cancer cell proliferation. J. Pineal Res., 14: 89-97, 1993.
26. Cos, S., Fernandez, F., and Sanchez-Barcelo, E. J. Influence of cell cycle phase on melatonin inhibitory action in MCF-7 cells. Colloq. Eur. Pineal Soc., , 1993.
27. Cos, S., and Sanchez-Barcelo, E. J. Differences between pulsatile or continuous exposure to the melatonin on MCF-7 human breast cancer cell proliferation. Cancer Lett., 85: 105-110, 1994.
28. Cos, S., and Sanehez-Barcelo, E. J. Melatonin inhibition of MCF-7 human breast cancer cell growth: influence of cell proliferation rate. Cancer Lett., 93: 207-212, 1995.
29. Crespo, D., Fernandez-Viadero, C., Verduga, R., Ovegero, V., and Cos, S. Interaction between melatonin and estradiol on morphological and morphometric features of MCF-7 human breast cancer cells. J. Pineal Res., 16: 215-222, 1994.
30. Furuya, Y., Yamamoto, K., Kohno, N., Ku, Y. S., and Saitoh, Y. 5-Fluorouracil attenuates an oncostatic effect of melatonin on estrogen-sensitive human breast cancer (MCF-7). Cancer Lett., 81: 95-98, 1994.
31. Blackman, C. F., Benane, S. G., House, D. E., and Blanchard, J. P. Independent replication of the 12-mG magnetic field effect on melatonin and MCF-7 cells in vitro. In: Prog. 18th Ann. Mtg. Bioelectromagnetics Society, pp. 1-2. Victoria, B. C., Canada, 1996.
32. Shellard, S. A., Whelan, R. D. H., and Hill, B. T. Growth-inhibitory and cytotoxic effects of melatonin and its metabolites on human tumor cell lines in vitro. Br. J. Cancer, 60: 288-290, 1989.
33. Bartsch, H., Bartsch, C., Noteborn, H. P. J. M., Flehmig, B., Ebels, I., and Salemink, C. A. Growth-inhibiting effect of crude pineal extracts on human melanoma cells in vitro is different from that of known synthetic pineal substances. J. Neural Transm., 69: 299-311, 1987.
34. L'Hermite-Baleriaux, M., and de Launoit, Y. Is melatonin really an in vitro inhibitor of human breast cancer cell proliferation? In Vitro Cell. Dev. Biol., 28A: 583-584, 1992.
35. Osborne, C. K., Hobbs, K., and Trent, J. M. Biological differences among MCF-7 human breast cancer cell lines from different laboratories. Breast Cancer Res. Treat., 9: 111-121, 1987.
36. Blask, D. E., and Hill, S. M. Effects of melatonin on cancer: studies on MCF-7 human breast cancer cells in culture. J. Neural Transm., 21 (Suppl.): 433-449, 1986.
37. Hill, S. M., and Blask, D. E. Melatonin inhibition of MCF-7 breast cancer cell proliferation; influence of serum factors, prolactin, and estrodial. Endocr. Soc., 68: 246, 1986.
38. Page, M. J., Field, J. K., Everett, N. P., and Green, C. D. Serum regulation of the estrogen responsiveness of the human breast cancer cell line MCF-7. Cancer Res., 43: 1244-1250, 1983.
39. Cos, S., and Blask, D. E. Melatonin modulates growth factor activity in MCF-7 human breast cancer cells. J. Pineal Res., 17: 25-32, 1994.
40. Lemus-Wilson, A., Kelly, P. A., and Blask, D. E. Melatonin blocks the stimulatory effects of prolactin on human breast cancer cell growth in culture. Br. J. Cancer, 72: 1435-1440, 1995.
41. Molis, T. M., Walters, M. R., and Hill, S. M. Melatonin modulation of estrogen receptor expression in MCF-7 human breast cancer cells. Int. J. Oncol., 3: 687-694, 1993.
42. Molis, T. M., Spriggs, L., and Hill, S. M. Modulation of estrogen receptor mRNA expression by melatonin in MCF-7 human breast cancer cells. Mol. Endocrinol., 8: 1681-1690, 1994.
43. Molis, T. M., Spriggs, L., Jupiter, Y., and Hill, S. M. Melatonin modulation of estrogen-regulated proteins, growth factors, and proto-oncogenes in human breast cancer. J. Pineal Res., 18: 93-103, 1995
44. Stankov, B., Scaglione, F., Lucini, V., and Fraschini, F. Specific binding in vitro and in vivo effects of melatonin on melanoma B16 and its metastatic growth. In: E. Rubinstein and D. Adams (eds.), Recent Advances in Chemotherapy, Proceedings of the 16th International Congress of Chemotherapy, p. 893.1. Jerusalem: Lewin-Epstein, 1989.
45. 125I]Iodomelatonin binding in normal and neoplastic tissues. In: F. Fraschini and R. Reiter (eds.), Role of Melatonin and Pineal Peptides in Neuroimmunomodulation, pp. 117-125. New York: Plenum Press, 1991.
46. Ying, S. W., Niles, L. P., and Crocker, C. Human malignant melanoma cells express high-affinity receptors for melatonin: antiproliferative effects of melatonin and 6-chloromelatonin. Eur. J. Pharmacol., 246: 89-96, 1993.
47. Burns, D. M., Cos Corral, S., and Blask, D. Demonstration and partial characterization of 2-iodomelatonin binding sites in experimental mammary cancer. Endocr. Soc., 72: 62, 1990.
48. Reppert, S. M., and Weaver, D. R. Melatonin madness. Cell, 83: 1059-1062, 1995.
49. Menendez-Pelaez, A., Poeggeler, B., Reiter, R. J., Barlow-Walden, L., Pablos, M. I., and Tan, D. X. Nuclear localization of melatonin in different mammalian tissues: immunocytochemical and radioimmunoassay evidence. J. Cell. Biochem., 53: 373-382, 1993.
50. Benitez-King, G., and Anton-Tay, F. Calmodulin mediates melatonin cytoskeletal effects. Experientia (Basel), 49: 635-641, 1993.
51. Reiter, R. J., Melchiorri, D., Sewerynek, E., Poeggeler, B., Barlow-Walden, L., Chuang, J., Ortiz, G. G., and Acuna-Castroviejo, D. A review of the evidence supporting melatonin's role as an antioxidant. J. Pineal Res., 18: 1-11, 1995.
52. Acuna-Castroviejo, D., Pablos, M. I., Menendez-Pelaez, A., and Reiter, R. J. Melatonin receptors in purified cell nuclei of liver. Res. Commun. Chem. Pathol. Pharmacol., 82: 253-256, 1993.
53. Carlberg, C., and Wiesenberg, I. The orphan receptor family RZR/ROR, melatonin, and 5-lipoxygenase: an unexpected relationship. J. Pineal Res., 18: 171-178, 1995.
54. Kothari, L., and Subramanian, A. A possible modulatory influence of melatonin on representative Phase I and Phase II drug metabolizing enzymes in 9,10-dimethyl-1,2-benzanthracene-induced rat mammary tumorigenesis. Anticancer Drugs, 3: 623-628, 1992.
55. Meister, A., and Anderson, M. E. Glutathione. Annu. Rev. Biochem., 52: 711-760, 1983.
56. Meister, A. Glutathione deficiency produced by inhibition of its synthesis, and its reversal: applications in research and therapy. Pharmacol. & Ther., 51: 155-194, 1991.
57. Arrick, B. A., and Nathan, C. F. Glutathione metabolism as a determinant of therapeutic efficacy: a review. Cancer Res., 44: 4224-4232, 1984.
58. Liebmann, J. E., Hahn, S. M., Cook, J. A., Lipschultz, C., Mitchell, J. B., and Kaufman, D. C. Glutathione depletion by L-buthionine sulfoximine antagonizes Taxol cytotoxicity. Cancer Res., 53: 2066-2070, 1993.
59. Ploemen, J., Van Ommen, B., and Van Bladeren, P. J. Inhibition of rat and human glutathione S-transferase isoenzymes by ethacrynic acid and its glutathione conjugate. Biochem. Pharmacol., 40: 1631-1635, 1990.
60. Anderson, M. Determination of glutathione and glutathione disulfide in biological samples. Methods Enzymol., 77: 548-555, 1985.
61. Shaw, J. P., and Chov, I. N. Elevation of intracellular glutathione content associated with mitogenic stimulation of quiescent fibroblasts. J. Cell. Physiol., 129: 193-198, 1986.
62. Ishikawa, T. The ATP-dependent glutathione S-conjugate export pump. Trends Biochem. Sci., 17: 463-468, 1992.
63. Jordan, V. C., and Murphy, C. S. Endocrine pharmacology of antiestrogens as antitumor agents. Endocr. Rev., 11: 578-610, 1990.
64. Leung, M. F., and Chov, I. N. Relationship between 1-chloro-2,4-dinitrobenzene-induced cytoskeletal perturbations and cellular glutathione. Cell Biol. Toxicol., 5: 51-99, 1989.
65. Benitez-King, G., and Anton-Tay, F. Calmodulin mediates melatonin cytoskeletal effects. Experientia (Basel), 49: 635-641, 1993.
66. Gupta, V., Kamath, N., Tkalcevic, G. T., and Singh, S. V. Potentiation of tamoxifen activity by verapamil in a human breast cancer cell line. Biochem. Pharmacol., 47: 1701-1704, 1994.
67. Poeggeler, B., Reiter, R. J., Hardeland, R., Sewerynek, E., Melchiorri, D., and Barlow-Walden, L. R. Melatonin, a mediator of electron transfer and repair reactions, acts synergistically with the chain-breaking antioxidants ascorbate, trolox, and glutathione. Neuroendocrinol. Lett., 19: 87-92, 1995.